“rna-interference” Archives

in
Entry Author Date Location
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact 06/01/20 New York
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics 03/25/20 Europe
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B 11/25/19 New York
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More 11/22/19 National
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug 10/31/19 Boston
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms 05/20/19 New York
Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPO 04/30/19 Boston
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More 04/19/19 National
Alnylam Makes Case For 2nd RNAi Drug at Big Liver Disease Meeting 04/12/19 Boston
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases 04/08/19 Boston
Data in Hand, Alnylam to Seek OK for Second RNAi Drug 03/06/19 Boston
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel 11/09/18 National
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M 10/29/18 Boston
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug 10/15/18 Boston
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Janssen Reaches $250M Deal for Rights to Arrowhead’s Hep B RNAi Drug 10/04/18 Wisconsin
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug 09/27/18 Boston
Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug 09/06/18 Wisconsin
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug 08/10/18 Boston
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More 08/10/18 National
Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More 08/03/18 National
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision 08/03/18 Boston
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot” 05/23/18 Boston
An Inside Look at CAR-T, Gene Therapy Launches at ‘What’s Hot’ May 16 05/09/18 Boston
Paying for Gene Therapy, CRISPR in People, RNAi at “What’s Hot” on May 16 03/05/18 Boston
LGC Acquires Lucigen, Marking Latest Exit for CEO Ralph Kauten 02/16/18 Wisconsin
Arrowhead Plans Return to Clinic With New Study of Hep B Drug 02/16/18 Wisconsin
Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs 01/11/18 National
In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward 12/15/17 Boston
Page 1 of 9 next page »